Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-Raises-2026-Full-Year-Financial-Guidance-Building-on-Strong-Second-Quarter-Results/default.aspx
Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2026-Investor-Update-Call/default.aspx
Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Appoints-Dr–Jeffrey-Silber-Chief-Medical-Officer-and-Head-of-Research-and-Drug-Development-STARS-2-Trial-Initiated-in-June-and-Is-Now-Actively-Recruiting-Patients/default.aspx
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-to-Participate-in-the-Jefferies-Global-Healthcare-Conference/default.aspx
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/FDA-Approves-Use-of-LINZESS-linaclotide-in-Pediatric-Patients-Two-Years-of-Age-and-Older-with-Functional-Constipation-FC/default.aspx
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-Reports-Strong-First-Quarter-2026-Results-With-97-Year-Over-Year-LINZESS-U-S–Net-Sales-Growth-Maintains-Full-Year-2026-Financial-Guidance/default.aspx
Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Survey-Findings-at-DDW-2026-Underscore-Need-for-Therapies-that-Address-Multiple-Dimensions-of-Total-Parenteral-Nutrition-TPN-Burden-in-Short-Bowel-Syndrome-SBS/default.aspx
Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-to-Host-First-Quarter-2026-Investor-Update-Call/default.aspx
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-to-Share-Real-World-HCP-Perspectives-on-Burden-of-Total-Parenteral-Nutrition-in-Short-Bowel-Syndrome-SBS-at-Digestive-Disease-Week-2026/default.aspx
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-to-Participate-in-The-Citizens-Life-Sciences-Conference/default.aspx